Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors

Cutaneous immune-related adverse events (cirAEs) are a heterogenous group of toxicities that affect 30–50% of patients on immune checkpoint inhibitor therapy (ICIs) [1,2]. On 14th February 2018, the National Comprehensive Cancer Network (NCCN) Guidelines for Management of Immunotherapy-Related Toxicities were introduced to guide treatment of select versus according to severity and morphology (Supplemental) [3]. However, adherence to these guideline recommendations remains unclear. We sought to evaluate cirAE treatment in a cohort of cancer patients receiving ICIs who developed cirAEs between 2016 and 2019, assess outcomes pre- and post-introduction of the original NCCN guidelines and identify factors associated with undertreatment.